



NOTICE OF PROPOSED RULEMAKING INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 855 BOARD OF PHARMACY

FILED

12/17/2025 1:22 PM
ARCHIVES DIVISION
SECRETARY OF STATE

FILING CAPTION: Protocols, Standard Vaccination Protocols and Formulary: Devices & Supplies

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 01/22/2026 10:00 AM

The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

HEARING(S)

Auxiliary aids for persons with disabilities are available upon advance request. Notify the contact listed above.

DATE: 01/22/2026

TIME: 9:45 AM

OFFICER: Rachel Melvin

REMOTE HEARING DETAILS

MEETING URL: [Click here to join the meeting](#)

PHONE NUMBER: 503-446-4951

CONFERENCE ID: 119065202

SPECIAL INSTRUCTIONS:

This hearing will be held virtually via Microsoft Teams.

If you wish to present oral testimony virtually during this hearing, sign up on our website at www.oregon.gov/pharmacy/pages/rulemaking-information or email your first and last name and email address to pharmacy.rulemaking@bop.oregon.gov. Please indicate which rule(s) you would like to comment on.

You must submit written comments before 10:00AM on January 22, 2026. Email written comments to pharmacy.rulemaking@bop.oregon.gov.

NEED FOR THE RULE(S)

Proposes adding new versions of HIV Post-Exposure Prophylaxis (PEP) protocol, HIV Pre-Exposure Prophylaxis (PrEP) protocol, adds Epinephrine to the Devices & Supplies Formulary, amends Coronavirus 19 vaccination protocol, amends Influenza vaccine protocol, amends current versions of the Standard Vaccination Protocols for Adults 18 Years of Age and Older & Assessment and Treatment Care Pathway and Standard Vaccination Protocol for Persons 7 through 17 Years of Age and Treatment Care Pathway by adding Chikungunya v. 5/13/2025. Permanently adopts Vaccination protocol for Managing Adverse Reactions v. 08/2025 and RSV vaccine protocol v. 09/2025. Repeals Standard Vaccination Protocol for 3 through 6 years of age and Standard Vaccination Protocol for 6 months through 2 years of age.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE

Standard Vaccination Protocol for Adults 18 Years of Age and Older & Assessment and Treatment Care Pathway

https://www.oregon.gov/pharmacy/Documents/DRAFT_Standard_Vaccination_Protocol_for_Adults_18_Years_of_Age_and_Older_Treatment_Care_Pathway_1.2026.pdf

Standard Vaccination Protocol for Persons 7 through 17 Years of Age & Assessment and Treatment Care Pathway

https://www.oregon.gov/pharmacy/Documents/DRAFT_Standard_Vaccination_Protocol_for_Persons_7_through_17_Years_of_Age_Treatment_Care_Pathway_1.2026.pdf

Standard Vaccination Protocol for Managing Adverse Reactions & Assessment and Treatment Care Pathway

https://www.oregon.gov/pharmacy/Documents/DRAFT_Standard_Vaccination_Protocol_for_Managing_Adverse_Reactions_Treatment_Care_Pathway_8.2025.pdf

REPEAL – Standard Vaccination Protocol for 3 through 6 Years of Age

https://www.oregon.gov/pharmacy/Documents/REPEAL_Standard_Vaccination_Protocol_for_3_through_6_Years_of_Age_9.17.2025.pdf

REPEAL – Standard Vaccination Protocol for 6 months through 2 Years of Age

https://www.oregon.gov/pharmacy/Documents/REPEAL_Standard_Vaccination_Protocol_for_6_months_through_2_Years_of_Age_9.17.2025.pdf

Preventative Care: HIV Post-Exposure Prophylaxis (PEP)

https://www.oregon.gov/pharmacy/Documents/DRAFT_PrevCare_PEP_Protocol_1.22.2026.pdf

Preventative Care: HIV Pre-Exposure Prophylaxis (PrEP)

https://www.oregon.gov/pharmacy/Documents/DRAFT_PrevCare_PrEP_Protocol_1.22.2026.pdf

Coronavirus 19 https://www.oregon.gov/pharmacy/Documents/DRAFT_PrevCare_IMZ_Coronavirus_19_1.2026.pdf

Influenza https://www.oregon.gov/pharmacy/Documents/DRAFT_PrevCare_IMZ_Influenza_1.2026.pdf

Respiratory Syncytial Virus

https://www.oregon.gov/pharmacy/Documents/DRAFT_PrevCare_IMZ_Respiratory_Syncytial_Virus_1.2026.pdf

Formulary: Devices & Supplies https://www.oregon.gov/pharmacy/Documents/Formulary_DevicesSupplies.pdf

STATEMENT IDENTIFYING HOW ADOPTION OF RULE(S) WILL AFFECT RACIAL EQUITY IN THIS STATE

The proposed rules may increase Oregonians access to the Coronavirus 19, Influenza and RSV vaccines, PEP and PrEP treatment, Chikungunya vaccine and Epinephrine.

FISCAL AND ECONOMIC IMPACT:

No fiscal anticipated. Licensees, registrants and interested parties will have an opportunity to provide fiscal and economic impact statements during the open comment period.

COST OF COMPLIANCE:

(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).

The proposed rule amendments will have no additional economic impact on state agencies, units of local government, the public or registrants or licensees who identify as a small business.

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Registrants who identify as a small business and who have signed up to receive notices will receive an email notice of proposed rulemaking via GovDelivery and will have an opportunity to provide public comment on the proposed rules

for the board's consideration.

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

No. Subject Matter Experts (SME) are responsible for drafting proposed amendments or draft protocols and the Public Health and Pharmacy Formulary Advisory Committee (PHPFAC) is responsible for recommending proposed or amended protocols to the board for consideration.

RULES PROPOSED:

855-115-0340, 855-115-0345

AMEND: 855-115-0340

RULE SUMMARY: Proposes amending current rule by adding Epinephrine to the Drug and Devices Formulary.

CHANGES TO RULE:

855-115-0340

Services: Prescribing - Formulary

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, an FDA-approved drug and device listed in the Formulary, pursuant to a diagnosis by a health care practitioner who has prescriptive authority and who is qualified to make the diagnosis. Formulary devices and supplies:¶¶

- (1) Diabetic blood sugar testing supplies;¶¶
- (2) Injection supplies;¶¶
- (3) Nebulizers and associated supplies;¶¶
- (4) Inhalation spacers;¶¶
- (5) Peak flow meters;¶¶
- (6) International Normalized Ratio (INR) testing supplies;¶¶
- (7) Enteral nutrition supplies; ¶¶
- (8) Ostomy products and supplies; and¶¶
- (9) Non-invasive blood pressure monitors; ~~and~~¶¶
- (10) Continuous glucose monitors and associated supplies; ~~and~~¶¶
- (11) Epinephrine.

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.645, ORS 689.649

AMEND: 855-115-0345

RULE SUMMARY: Proposes amending current rule by adding new versions for HIV Post-Exposure Prophylaxis (PEP) protocol, HIV Pre-Exposure Prophylaxis (PrEP) protocol, amends Coronavirus 19 vaccination protocol, amends Influenza vaccine protocol, permanently adopts Respiratory Syncytial Virus protocol v. 09/2025, amends current versions of the Vaccination Protocol for Adults 18 Years of Age and Older & Assessment and Treatment Care Pathway and Vaccination Protocol for Persons 7 through 17 Years of Age and Treatment Care Pathway by adding Chikungunya v. 5/13/2025. Adopts Managing Adverse Reactions protocol v. 08/2025. Repeals Vaccination Protocol for Ages 3 through 6 Years (v. 08/13/2025) and Vaccination Protocol for Ages 6 months through 2 Years v. 08/13/2025.

CHANGES TO RULE:

855-115-0345

Services: Prescribing Pursuant to - Protocol

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices pursuant to a Protocol. Protocols in their entirety are adopted by the board by this rule pursuant to the respective effective date referenced and can be found on the board website at

<https://www.oregon.gov/pharmacy/Pages/PFAC.aspx>

(1) Continuation of therapy Protocol including emergency refills of insulin and early refills of opioid use disorder medications (v. 08/2024)

(2) Conditions Protocols:

(a) Cough and cold symptom management

(A) Benzonatate (v. 06/2021);

(B) Short-acting beta agonists (v. 06/2021);

(C) Intranasal corticosteroids (v. 06/2021);

(b) COVID-19 Antigen Self-Test (v. 12/2021);

(c) SARS-CoV-2 Antiviral (v. 08/2024)

(3) Preventative Care Protocols:

(a) Emergency Contraception (v. 06/2021);

(b) Male and female condoms (v. 06/2021);

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);

(d) Travel Medications (v. 06/2024);

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 06/2023);

(g) Contraception (v. 06/2025);

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);

(i) Short-acting Opioid Antagonists (v. 06/2024); and

(4) Vaccine Protocols:

(a) Vaccination Protocol for Adults 18 Years of Age and Older (v. 08/2025);

(b) Vaccination Protocol for Ages 7 through 17 Years (v. 08/2025); and

(c) Vaccination Protocol for Ages 3 through 6 Years (v. 08/2025);

(d) Managing Adverse Reactions (v. 08/2025).

(5) Board Excluded Vaccination Protocol for Ages 6 months through 2 Years

(a) Coronavirus 19 (v. 01/2026);

(b) Influenza (v. 08/2025); and

(c) Vaccination Protocol for Managing Adverse Reaction Respiratory Syncytial Virus (v. 08/2025).

[Publications: Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205, ORS 689.005

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.005